Medical treatment of endometriosis

Chang Gung Medical Journal

Volumn 31, Issue 5, 2008, Pages 431-440

  Huang, Hong Yuan ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Aromatase inhibitor; Endometriosis; Gonadotropin releasing hormone; Progestin

Indexed keywords

ANASTROZOLE; ANDROGEN; ANTIGESTAGEN; AROMATASE INHIBITOR; ASOPRISNIL; CETRORELIX; CYPROTERONE ACETATE; DANAZOL; GESTAGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; GOSERELIN; LETROZOLE; LEVONORGESTREL; LOXORIBINE; MATRIX METALLOPROTEINASE; MIFEPRISTONE; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PENTOXIFYLLINE; PLACEBO; PROGESTERONE RECEPTOR MODULATOR;

ACNE; ADRENAL DISEASE; ANGIOGENESIS; AROMATIZATION; BONE DENSITY; BREAST ATROPHY; BREAST CANCER; CELL LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DYSMENORRHEA; DYSPAREUNIA; ENDOMETRIOSIS; ENZYME ACTIVITY; GONADOTROPIN RELEASE; HEADACHE; HIRSUTISM; HOT FLUSH; HUMAN; HYPOADRENALISM; HYPOESTROGENISM; INFERTILITY; INTRAUTERINE CONTRACEPTIVE DEVICE; LARYNX DISORDER; LEIOMYOMA; LIBIDO; MENOPAUSAL SYNDROME; MENORRHAGIA; MENSTRUAL CYCLE; MENSTRUATION; MOLECULAR DYNAMICS; MONOTHERAPY; MOOD DISORDER; ORAL CONTRACEPTION; OUTCOME ASSESSMENT; PATHOGENESIS; PELVIS PAIN SYNDROME; PRECOCIOUS PUBERTY; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; RASPY VOICE; RECURRENT DISEASE; REOPERATION; REVIEW; SIDE EFFECT; STEROIDOGENESIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UTERUS MYOMA; VAGINAL DRYNESS; WEIGHT GAIN;

ENDOMETRIOSIS; FEMALE; HUMANS;

EID: 54349105232     PISSN: 02558270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Houston DE, Noller KL, Melton LJ, Selwyn BJ. The epidemiology of pelvic endometriosis. Clin Obstet Gynecol 1988;31:787-800.
2. Cramer DW, Missmer SA. The epidemiology of endometriosis. Ann N Y Acad Sci 2002;955:11-22.
3. Sensky TE, Liu DT. Endometriosis: associations with menorrhagia, infertility and oral contraceptives. Int J Gynaecol Obstet 1980;17:573-6.
4. Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin North Am 1997;24:235-58.
5. Crosignani P, Olive D, Bergqvist A, Luciano A. Advances in the management of endometriosis: an update for clinicians. Hum Reprod Update 2006;12:179-89.
6. American Fertility Society. Classification of endometriosis. Fertil Steril 1979;32:633-45.
7. American Fertility Society. Revised American Fertility Society Classification of endometriosis. Fertil Steril 1985;43:351-2.
8. Kuohung W, Jones GL, Vitonis AF, Cramer DW, Kennedy SH, Thomas D, Hornstein MD. Characteristics of patients with endometriosis in the United States and the United Kingdom. Fertil Steril 2002;78:767-72.
9. Candiani GB, Fedele L, Vercellini P, Bianchi S, DiNola G. Repetitive conservative surgery for recurrence of endometriosis. Obstet Gynecol 1991;77:421-4.
10. Practice Committee of the American Society for Reproductive Medicine. Endometriosis and infertility. Fertil Steril 2004;81:1441-6.
11. Olive DL, Lindheim SR, Pritts EA. New medical treatments for endometriosis. Best Pract Res Clin Obstet Gynaecol 2004;18:319-28.
12. Lessey BA. Medical management of endometriosis and infertility. Fertil Steril 2000;73:1089-96.
13. Valle RF, Sciarra JJ. Endometriosis: treatment strategies. Ann N Y Acad Sci 2003;997:229-39.
14. Wheeler JM, Knittle JD, Miller JD. Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. I. Efficacy results. Am J Obstet Gynecol 1992;167:1367-71.
15. Rock JA, Truglia JA, Caplan RJ. Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. The Zoladex Endometriosis Study Group. Obstet Gynecol 1993;82:198-205.
16. Ferrero S, Abbamonte LH, Anserini P, Remorgida V, Ragni N. Future perspectives in medical treatment of endometriosis. Obstet Gynecol Surv 2005;60:817-26.
17. Vercellini P, Trespidi L, Colombo A. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1993;60:75-9.
18. Waller KG, Shaw RW. Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertil Steril 1993;59:511-5.
19. Vercellini P, Trespidi L, DeGiorgi O, Cortesi I, Parazzini F, Crosignani PG. Endometriosis and pelvic pain. Relation to disease stage and localization. Fertil Steril 1996;65:299-304.
20. Rice VM. Conventional medical therapies for endometriosis. Ann N Y Acad Sci 2002;955:343-52.
21. Vercellini P, De Giorgi O, Mosconi P, Stellato G, Vicentini S, Crosignani PG. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril 2002;77:52-61.
22. Hompes PG, Mijatovic V. Endometriosis: the way forward. Gynecol Endocrinol 2007;23:5-12.
23. Olive DL. Medical therapy of endometriosis. Semin Reprod Med 2003;21:209-22.
24. Oral E, Arici A. Peritoneal growth factors and endometriosis. Semin Reprod Endocrinol 1996;14:257-67.
25. Dmowski WP, Cohen MR. Treatment of endometriosis with an antigonadotropin, danazol: A laparoscopic and histologic evaluation. Obstet Gynecol 1975;46:147-54.
26. Buttram VC, Reiter RC, Ward S. Treatment of endometriosis with danazol: report of a 6-year prospective study. Fertil Steril 1985;43:353-60.
27. Kauppila A. Changing concepts of medical treatment of endometriosis. Acta Obstet Gynecol Scand 1993;72:324-36.
28. Mizutani T, Nishiyama S, Amakawa I, Watanabe A, Nakamuro K, Terada N. Danazol concentrations in ovary, uterus, and serum and their effect on the hypothalamic-pituitary-ovarian axis during vaginal administration of a danazol suppository. Fertil Steril 1995;63:1184-9.
29. Igarashi M, Iizuka M, Abe Y, Ibuki Y. Novel vaginal danazol ring therapy for pelvic endometriosis, in particular deeply infiltrating endometriosis. Hum Reprod 1998;13:1952-6.
30. Cobellis L, Razzi S, Fava A, Severi FM, Igarashi M, Petraglia F. A danazol-loaded intrauterine device decreases dysmenorrhea, pelvic pain, and dyspareunia associated with endometriosis. Fertil Steril 2004;82:239-40.
31. Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. N Engl J Med 1988;318:485-9.
32. Kennedy SH, Williams IA, Brodribb J, Barlow DH, Shaw RW. A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertil Steril 1990;53:998-1003.
33. The Nafarelin European Endometriosis Trial Group (NEET). Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up. Fertil Steril 1992;57:514-22.
34. Barbieri RL, Evans S, Kistner RW. Danazol in the treatment of endometriosis: analysis of 100 cases with a 4-year follow-up. Fertil Steril 1982;37:737-46.
35. Pellicer A, Simon C, Miro F, Castellvi RM, Ruiz A, Ruiz M, Perez M, Bonilla-Musoles F. Ovarian response and outcome of in-vitro fertilization in patients treated with gonadotropin-releasing hormone analogues in different phases of the menstrual cycle. Hum Reprod 1989;4:285-9.
36. Pellicer A, Tarin JJ, Miro' F, Sampaio M, De los Santos MJ, Remohi J. The use of gonadotropin releasing-hormone analogues (GnRHa), in in-vitro fertilization: some clinical and experimental investigations of a direct effect on the human ovary. Hum Reprod 1992;7:39-47.
37. Emons G, Schally AV. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod 1994;9:1364-79.
38. Chegini N, Rong H, Dou Q, Kipersztok, Williams RS. Gonadotropin-releasing hormone (GnRH) and GnRH receptor gene expression in human myometrium and leiomiomata and the direct action of GnRH analogs on myometrial smooth muscle cells and interaction with ovarian steroids in vitro. J Clin Endocrinol Metab 1996;81:3215-22.
39. Hsueh AJW, Jones PBC. Extrapituitary actions of gonadotropin releasing hormone. Endocr Rev 1981;2:437-55.
40. Sagsveen M, Farmer JE, Prentice A, Breeze A. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev 2003;4:CD001297.
41. Waller KG, Shaw RW. Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertil Steril 1993;59:511-5.
42. Greep RO, Van Dyke HB, Chow BF. Gonadotropin of swine pituitary: various biological effects of purified thylkentrin (FSH) and pure matakentrin (ICSH). Endocrinology 1942;30:635-49.
43. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994;15:342-55.
44. Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K, Speed C, Jones M. Aromatase-a brief overview. Annu Rev Physiol 2002;64:93-127.
45. Bulun SE, Zeitoun K, Takayama K, Noble L, Michael D, Simpson E, Johns A, Putman M, Sasano H. Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis. Endocr Relat Cancer 1999;6:293-301.
46. Zeitoun KM, Bulun SE. Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target. Fertil Steril 1999;72:961-9.
47. Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 2001;7:2620-35.
48. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001;19:881-94.
49. Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 2002;95:2006-16.
50. Santen RJ, Harvey HA. Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer 1999;6:75-92.
51. Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, Bang H. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 2006;91:3885-90.
52. Ailawadi RK, Jobanputra S, Kataria M, Gurates B, Bulun SE. Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril 2004;81:290-6.
53. Shippen ER, West WJ Jr. Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil Steril 2004;81:1395-8.
54. Soysal S, Soysal ME, Ozer S, Gul N, Gezgin T. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod 2004;19:160-7.
55. Attar E, Bulun SE. Aromatase inhibitors: the next generation of therapeutics for endometriosis? Fertil Steril 2006;85:1307-18.
56. Huirne JA, Lambalk CB. Gonadotropin-releasing-hormone-receptor antagonists. Lancet 2001;358:1793-803.
57. Griesinger G, Felberbaum R, Diedrich K. GnRH-antagonists in reproductive medicine. Arch Gynecol Obstet 2005;273:71-8.
58. Jones RC. The effect of a luteinizing hormone-releasing hormone antagonist on experimental endometriosis in the rat. Acta Endocrinol 1987;114:379-82.
59. Kupker W, Felberbaum RE, Krapp M, Schill T, Malik E, Diedrich K. Use of GnRH antagonists in the treatment of endometriosis. Reprod Biomed Online 2002;5:12-6.
60. Finas D, Hornung D, Diedrich K, Schultze-Mosgau A. Cetrorelix in the treatment of female infertility and endometriosis. Expert Opin Pharmacother 2006;7:2155-68.
61. Murphy AA, Zhou MH, Malkapuram S, Santanam N, Parthasarathy S, Sidell N. RU486-induced growth inhibition of human endometrial cells. Fertil Steril 2000;74:1014-9.
62. Jiang J, Wu RF, Wang ZH, Sun HC, Xu Z, Xiu HM. Effect of mifepristone on estrogen and progesterone receptors in human endometrial and endometriotic cells in vitro. Fertil Steril 2002;77:995-1000.
63. Grow DR, Williams RF, Hsiu JG, Hodgen GD. Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study. J Clin Endocrinol Metab 1996;81:1933-9.
64. Kettel LM, Murphy AA, Mortola JF, Liu JH, Ulmann A, Yen SS. Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis. Fertil Steril 1991;56:402-7.
65. Kettel LM, Murphy AA, Morales AJ, Yen SS. Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum Reprod 1994;9(suppl 1):116-20.
66. Kettel LM, Murphy AA, Morales AJ, Ulmann A, Baulieu EE, Yen SS. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril 1996;65:23-8.
67. Kettel LM, Murphy AA, Morales AJ, Yen SS. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol 1998;178:1151-6.
68. Elger W, Bartley J, Schneider B, Kaufmann G, Schubert G, Chwalisz K. Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids 2000;65:713-23.
69. Chwalisz K, Garg R, Brenner RM, Schubert G, Elger W. Selective progesterone receptor modulators (SPRMs): a novel therapeutic concept in endometriosis. Ann N Y Acad Sci 2002;955:373-88.
70. DeManno D, Elger W, Garg R, Lee R, Schneider B, Hess-Stumpp H, Schubert G, Chwalisz K. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 2003;68:1019-32.
71. Chwalisz K, Mattia-Goldberg K, Lee M, Elger W, Edmonds A. Treatment of endometriosis with the novel selective progesterone receptor modulator (SPRM) asoprisnil. Fertil Steril 2004;82:S83-4.
72. Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005;26:423-38.
73. Luukkainen T, Lahteenmaki P, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann Med 1990;22:85-90.
74. Lockhat, FB, Emembolu JO, Konje JC. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod 2005;20:789-93.
75. Bahamondes L, Petta CA, Fernandes A, Monteiro I. Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea. Contraception 2007;75:S134-9.
76. Petta CA, Ferriani RA, Abrao MS, Hassan D, Rosa E Silva JC, Podgaec S, Bahamondes L. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod 2005;20:1993-8.
77. D'Antonio M, Martelli F, Peano S, Papoian R, Borrelli F. Ability of recombinant human TNF binding protein-1 (rhTBP-1) to inhibit the development of experimentally-induced endometriosis in rats. J Reprod Immunol 2000;48:81-98.
78. Huang HY, Wen Y, Irwin JC, Kruessel JS, Soong YK, Polan ML. Cytokine mediated regulation of 92-kilodalton type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-3 messenger ribonucleic acid expression in human endometrial stromal cells. J Clin Endocrinol Metab 1998;83:1721-9.
79. Huang HY. The cytokine network during embryo implantation. Chang Gung Med J 2006;29:25-36.
80. Bruner KL, Matrisian LM, Rodgers WH, Gorstein F, Osteen KG. Suppression of matrix metalloproteinases inhibits establishment of ectopic lesions by human endometrium in nude mice. J Clin Invest 1997;99:2851-7.
81. Huang HY, Chan SH, Yu HT, Wang HS, Lai CH, Soong YK. Interleukin-18 system messenger ribonucleic acid and protein expression in human endometrium during menstrual cycle. Fertil Steril 2006;86:905-13.
82. Somigliana E, Vigano P, Rossi G, Carinelli S, Vignali M, Panina-Bordignon P. Endometrial ability to implant in ectopic sites can be prevented by interleukin-12 in a murine model of endometriosis. Hum Reprod 1999;14:2944-50.